References

ateroskleroz

Атеросклероз

Ateroscleroz

2078-256X2949-3633

НИИТПМ-филиал ИЦиГ СО РАН

ateroskleroz-31

Research Article

Статьи

«НОВЫЙ» ПАТОЛОГИЧЕСКИЙ КОНТИНУУМ: ГИПОГОНАДИЗМ, ОСТЕОПОРОЗ И КАЛЬЦИНИРУЮЩИЙ АТЕРОСКЛЕРОЗ. ОБЩИЕ ФАКТОРЫ ФОРМИРОВАНИЯ И ПРОГРЕССИРОВАНИЯ

NEW" PATHOLOGICAL CONTINUUM: A HYPOGONADISM, AN OSTEOPOROSIS AND THE CALCINATING ATHEROSCLEROSIS. GENERAL FACTORS OF FORMATION AND PROGRESSION

Кашталап

В. В.

Kashtalap

V. V.

v_kash@mail.ru

Хрячкова

О. Н.

Hryachkova

O. N.

oksana_hryachkova@mail.ru

Барбараш

О. Л.

Barbarash

O. L.

olb61@mail.ru

Федеральное государственное бюджетное научное учреждение «Научноисследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Кемеровский государственный медицинский университет» Минздрава РоссииFederal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases"; Federal State Budget Educational Institution of Higher Education “Kemerovo State Medical University”, the Ministry of Health of the Russian Federation

Федеральное государственное бюджетное научное учреждение «Научноисследовательский институт комплексных проблем сердечно-сосудистых заболеваний»Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases"

2016

27092019

1246878

2019

Кашталап В.В., Хрячкова О.Н., Барбараш О.Л.

Kashtalap V.V., Hryachkova O.N., Barbarash O.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://ateroskleroz.elpub.ru/jour/article/view/31

В обзоре освещены современные представления о связи андрогенного дефицита, остеопороза и эктопической кальцификации у пациентов с различными заболеваниями. Обсуждены биомаркеры метаболизма костной ткани, информативные в отношении оценки тяжести этих состояний и перспективные для улучшения подходов к оценке риска. Для составления обзорной статьи использованы доступные материалы из зарубежных библиотечных баз данных (Library's MEDLINE/Pub Med database).

Modern ideas of communication of androgenic deficiency, an osteoporosis and an ectopic calcareous infiltration at patients with various diseases are covered in the review. In this article the bone tissue metabolism’biomarkers were discussed as informative for risk assessment in men with coronary artery disease. The review article summarizes available materials from foreign medical databases including MEDLINE and PubMed.

гипогонадизмтестостероностеопорозбиомаркеры метаболизма костной тканикальцификацияоценка риска

hypogonadismtestosteroneosteoporosisbone tissue metabolism biomarkerscalcificationrisk assessment

References1

Ridker P. Is Statin Monotherapy the Perfect Polypill? Circulation. 2016;134:91-93.

Fruchart J. C., Nierman M. C., Stoes E. S. G., Kastelein J. J. P., Duriez P. New risk factors for atherosclerosis and patient risk factor assessment. Circulation. 2004; 109 (Suppl): 15-19.

Ettinger B., Pressman A., Sklarin P., Bauer D. C., Cauley J. A., Cummings S. R. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 1998;83 (7):2239-2243.

Egleston B. L., Chandler D. W., Dorgan J. F. Validity of estimating non-sex hormone-binding globulin bound testosterone and oestradiol from total hormone measurements in boys and girls. Ann Clin Biochem. 2010;47 (Pt 3):233-241.

Tyuzikov I. A., Kalinchenko S. Yu. Androgenic deficiency in the general medical practice: endocrinology, rational diagnostics and clinical masks. Medical alphabet. Hospital - all for LPU. 2012; 1:13-19. In Russian. Тюзиков И. А., Калинченко С. Ю. Андрогенный дефицит в общей врачебной практике: эндокринология, рациональная диагностика и клинические маски. Медицинский алфавит. Больница - вся для ЛПУ. 2012; 1:13-19.

Daniel K. M., Jones T. H. Testosterone and Cardiovascular Risk in Men. Granata R, Isgaard J (eds): Cardiovascular Issues in Endocrinology. Front Horm Res. Basel, Karger, 2014, vol 43, pp 1-20 DOI: 10.1159/000360553.

Fahed A. C., Gholmieh J. M., Azar S. T. Connecting the Lines between Hypogonadism and Atherosclerosis. International Journal of Endocrinology. 2012, Article ID 793953, 12 pages doi:10.1155/2012/793953.

Jones T. H. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010; 21: 496-503.

Araujo A. B., Dixon J. M., Suarez E. A., Murad M. H., Guey L. T., Wittert G. A. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96: 3007-3019.

Jackenhovel F. Male Hypogonadism. AuflageBremen: Uni-Med, 2004. - 185 p.

Yeap B. B. Androgens and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2010;17:269 -276.

Erectile dysfunction in young and middle aged men with arterial hypertension and coronary heart disease. Barbarash O. L., Davidovich I. M., Pomeshkina S. A., Marenin S. N. Kemerovo. “Kuzbassvuzizdat”. 2015. - 142 p. In Russian. Эректильная дисфункция у мужчин молодого и среднего возраста с артериальной гипертензией и ишемической болезнью сердца./О. Л. Барбараш, И. М. Давидович, С. А. Помешкина, С. Н. Маренин. - Кемерово: АИ «Кузбассвузиздат», 2015. - 142 с.

Gorbachinsky I. Metabolic Syndrome and Urological Diseases. Rev Urol. 2010; 12 (4):157-180.

Muraleedharan V., Jones T. H. Testosterone and mortality. Clinical Endocrinology. 2014; 81, 477-487.

Ohlsson C., Barrett-Connor E., Bhasin S., Orwoll E., Labrie F., Karlsson M. K., Ljunggren O., Vandenput L., Mellstrom D., Tivesten A. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) Study in Sweden. J Am Coll Cardiol 2011; 58: 1674-1681.

Muraleedharan V., Marsh H., Kapoor D., Channer K. S., Jones T. H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013; 169: 725-733.

Kelly D. M., Jones T. H. Testosterone: a vascular hormone in health and disease. J Endocrinol 2013; 217: R47 - R71.

Haddad R. M., Kennedy C. C., Caples S. M., Tracz M. J., Bolona E. R., Sideras K., Uraga M. V., Erwin P. J., Montori V. M. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007; 82: 29-39.

Camici G. G., Savarese G., Akhmedov A., Luscher T. F. Molecular mechanism of endothelial and vascular ageing: implications for cardiovascular disease. Eur Heart J. 2015; 36:3392-3403.

Vigen R., O’Donnell C. I., Baron A. E., Grunwald G. K., Maddox T. M., Bradley S. M., Barqawi A., Woning G., Wierman M. E., Plomondon M. E., Rumsfeld J. S., Ho P. M. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013; 310: 1829- 1836.

Svartberg J., von Muhlen D., Mathiesen E., Joakimsen O., Bonaa K. H., Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J. Intern. Med. 2006; 259:576-582.

Kapoor D., Clarke S., Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. EurJ Endocrinol. 2007; 156:596-602. 23. Hamerman D. Bone health across the generations. A primer for health providers concerned with osteoporosis prevention. Maturitas 2004; 50:1-7.

Sennerby U., Melhus H., Gedeborg R. Cardiovascular diseases and risk of hip fracture. JAMA. 2009; 302: 1666-1673.

Lopez A. D., Murray C. C. The global burden of disease, 1990-2020. Nat Med 1998; 4:1241-1243. 26. Vertkin A. L., Naumov A. V., Ivanov V. S. Osteoporosis in patients with cardiovascular diseases. Modern rheumatology 2008; 1:52-59. In Russian. Верткин А. Л., НаумовА. В., ИвановВ. С. Остеопороз у пациентов с сердечно-сосудистыми заболеваниями. Современная ревматология. 2008; 1:52- 59.

Marcovitz P. A., Tran H. H., Franklin B. A. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 2005; 96: 1059-1063.

Qaseem A., Snow V., Shekelle P., Hopkins Jr, Forciea M. A., Owens D. K. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. AnnInternMed. 2008;148 (9):680-684. http://dx.doi.org/10.7326/00 03-4819-148-9-200805060-00008

Skripnikova I. A., Scheplyagina L. A., Novikov V. E., Kosmatova O. V., Abirova A. S. Possibilities of an osteal x-ray densitometry in clinical practice (methodical references). Moscow. 2015. -37 p. In Russian. Скрипникова И. А., Щеплягина Л. А., Новиков В. Е., Косматова О. В., Абирова А. С. Возможности костной рентгеновской денситометрии в клинической практике (методические рекомендации). Москва. 2015. -37 c.

Broussard D. L., Magnus J. H. Coronary heart disease risk and bone mineral density among U. S. women and men. J Women’s Health. 2008; 17: 479-490.

Lewiecki E., Gordon C., Baim S. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008; 43 (6):1115- 1121. http://dx.doi.org/10.1016/j. bone. 2008.08.106.

Waller A. H., Sanchez-Ross M., Kaluski E., Klapholz M. Osteopontin in cardiovascular disease. A potential therapeutic target. Cardiol Rev. 2010; 18: 125-131.

Hsu B., Cumming R. G., Naganathan V. Longitudinal relationships of circulating reproductive hormone with functional disability, muscle mass, and strength in community-dwelling older men: the Concord Health and Ageing in Men project. J Clin Endocrinol Metab. 2014;99 (9):3310-3318.

Lesnyak OM, Benevolenskaya LI. Osteoporoz. Klinicheskie rekomendatsii. Moscow: GEOTARmedia; 2009. - 272 p. In Russian. Лесняк ОМ, Беневоленская ЛИ. Остеопороз. Клинические рекомендации. Москва: ГЭОТАР-медиа; 2009. - 272 c.

Zverev Ya. F., Zharikov A. Yu., Brukhanov V. M., Lampatov V. V. Modulators of oxalate nephrolithiasis. Inhibitors’ crystallization. Nephrology. 2010; 14 (1): 29-49. in Russian. Зверев Я. Ф., Жариков А. Ю., Брюханов В. М., Лампатов В. В. Модуляторы оксалатного нефролитиаза. Ингибиторы кристаллизации. Нефрология. 2010; 14 (1): 29-49.

Barascuk N., Skjβt-Arkil H., Register T. C., Larsen L., Byrjalsen I., Christiansen C., Karsdal M. A. Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes. BMC CardiovascularDisorders. 2010; 10:19.

Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Luthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89:309-319.

Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circres. 2004; 95:1046-1057.

Stagi S., Di Tommaso M., Manoni C., Scalini P., Chiarelli F., Verrotti A., Lapi E., Giglio S., Dosa L., de Martino M. Bone Mineral Status in Children and Adolescents with Klinefelter Syndrome. Int J Endocrinol. 2016;2016:3032759. doi: 10.1155/2016/3032759.

Stagi S., Iurato C., Lapi E., Cavalli L., Brandi M. L., de Martino M. Bone status in genetic syndromes: a review, Hormones. 2015; 14 (1):19-31.

Ferlin A., Selice R., Di Mambro A. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome. Osteoporosis International, 2015; 26 (8):2193-2202.

Yeh S.-S., Phanumas D., Hafner A., Schuster M. W. Risk factors for osteoporosis in a subgroup of elderly men in a Veterans Administration nursing home. Journal of Investigative Medicine, 2002; 50 (6): 452-457.

Yarram S. J., Perry M. J., Christopher T. J. Luteinizing hormone receptor knockout (LuRKO) mice and transgenic human chorionic gonadotropin (hCG) - overexpressing mice (hCG????????+) have bone phenotypes. Endocrinology. 2003; 144 (8):3555- 3564.

Francis R. M., Peacock M., Aaron J. E. Osteoporosis in hypogonadal men: role of decreased plasma 1,25dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone. 1986; 7 (4):261-268. 45. Permpongkosol S, Khupulsup K, Leelaphiwat S, Pavavattananusorn S, Thongpradit S, Petchthong T. Effects of 8-Year Treatment of LongActing Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With LateOnset Hypogonadism. J Sex Med. 2016; 13 (8):1199- 211. doi: 10.1016/j. jsxm. 2016.06.003.

Mshakaya G. J., Tishova Yu. A., Kalinchenko S. Yu. Influence of androgenic deficiency on the mineral density of a bone tissue at men. Farmateka. 2007; 139 (4): 75-78. In Russian. Мсхалая Г. Ж., Тишова Ю. А., Калинченко С. Ю. Влияние андрогенного дефицита на минеральную плотность костной ткани у мужчин. Фарматека. 2007; 139 (4): 75-78.

Boyanov M. A., Boneva Z., Christov V. G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. AgingMale. 2003;6:1-7.

Saad F., Haider A., Doros G., Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013; 21: 1975-1981.

Srinivas-Shankar U., Roberts S. A., Connolly M. J., O’Connell M. D., Adams J. E., Oldham J. A., Wu F. C. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010; 95: 639-650.

Niskanen L., Laaksonen D. E., Punnonen K. Changes in sex hormone-binding giobulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes. Metab. 2004; 6:208-215.

DeFina L. F., Leonard D., Willis B. L., Barlow C. E., Finley C. E., Jenkins M. R., Pence B. C., Zhang Y., Chyu M.-C., Lewiecki E. M., Shen C.-Li, High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women. Journal of women’s health. 2016. DOI: 10.1089/jwh. 2014.5170.

Hsu B., Seibel M. J., Cumming R. G., Blyth F. M., Naganathan V., Bleicher K., Le Couteur D. G., Waite L. M., Handelsman D. J. Progressive Temporal Change in Serum SHBG, but not in Serum Testosterone or Estradiol, Is Associated with BoneLoss and Incident Fractures in Older Men: The Concord Health and Ageing in Men Project. J Bone Miner Res. 2016 Jul 1. doi: 10.1002/jbmr. 2904.

Stadler E. R. Identification of general factors’ development of osteopenic syndrome and arterial hypertension in teenagers. Postgraduate bulletin of the Volga region. 2014; 1-2: 139-141. in Russian. Стадлер Е. Р. Выявление общих факторов развития остеопенического синдрома и артериальной гипертензии у подростков. Аспирантский вестник Поволжья. 2014; 1-2: 139-141.

McFarlane S. I., Muniyappa R., Shin J. J., Bahitiyar G., Sowers J. R. Osteoporosis and cardiovascular disesase: brittle bones and boned arteries - is there a link? Endocrine. 2004; 23:1-10.

Giachelli C. M., Bae N., Almeida M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaque. J Clin Invest. 2003;92:1686-1696.

Raaz-Schrauder D., Klinghammer L., Baum C., Frank T., Lewczuk P., Achenbach S., Cicha I., Stumpf C., Wiltfang J., Kornhuber J., Daniel W. G., Garlichs C. D. Association of systemic inflammation markers with the presence and extent of coronary artery calcification. Cytokine. 2012;

: 251-257. 57. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., Simonet W. S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development. 1998; 12:1260-1268.

Boekholdt S. M., Hovingh G. K., Mora S., Arsenault B. J., Amarenco P., Pedersen T. R. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. JACC. 2014; 5 (64): 485-494.

Barbarash O. L., Lebedeva N. B., Kokov A. N., Novitskaya A. A., Hryachkova O. N., Voronkina A. V., Raskina T. A., Kashtalap V. V., Kutikhin A. G., Shibanova I. A. Decreased Cathepsin K Plasma Level may Reflect an Association of Osteopoenia/osteoporosis with Coronary Atherosclerosis and Coronary Artery Calcification in Male Patients with Stable Angina. Heart, Lung and Circulation. 2016; xx:1-7. 1443-9506/04/$ 36.00. http://dx.doi.org/10.1016/j. hlc. 2016.02.002.

London G. M., Guerin A. P., Marchais S. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18:1731-1740.

Shah R. V., Murthy V. L. Cardiac magnetic resonance detection of the human carotid: A new lens on neovascularization? Atherosclerosis. 2016;245: 60-61. http://dx.doi.org/10.1016/j. atherosclerosis. 2015.12.003

Agatston A. S., Janowitz W. R., Hildner F. J., Zusmer N. R., Viamonte M. Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. JAmCollCardiol. 1990;15:827-32.

Demer L. L. Vascular calcification and osteoporosis: inflammatory responses to oxidizied lipids. Intl J Epidemiol. 2002; 31:737-741.

Mason J. C., Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. EurHeartJ. 2015;36:482-489. 65. Simpson C. LS., Lindley S., Eisenberg C., Basalyga D. M., Starchet B. C., Simonescu D. T., Vyavahare N. R. Toward cell therapy for vascular calcification: osteoclastmediated demineralization of calcified elastin. CardiovascularPathology. 2007; 16:29-37.

Sugihara N., Matsuzaki M., Kato Y. The relation between bone calcium metabolism and senile aortic valve calcification. Nippon Ronen Igakkai Zasshi. 1992; 29:403-410.

Paita S., Pai A. M., Gill K. S. New insight into the progression of aortic stenosis: implication for secondary prevention. Circulation. 2000;101:2497-2502.

Nishizava Y., Morii H. Osteoporosis and atherosclerosis in chronic renal failure. Osteoporosis Int. 2004; 7: Suppl 3: S188-192.

Stefenelli T., Mayer H., Berger-Klein J. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. AmJMed. 2003;95:197-202.

Herziger D. Organ transplantation and osteoporosis. Current Opinionin Rheumatol. 1996; 773:255-261.

Ermolenko V. M., Mikhailova N. A., BatYerdyene C. Physiology and pathophysiology of phosphates’ transport. Nephrology. 2007; 11 (3):12- 20. In Russian. Ермоленко В. М., Михайлова Н. А., Бат-Эрдэнэ С. Физиология и патофизиология транспорта фосфата. Нефрология. 2007; 11 (3):12-20. 72. Zemchenkov A. Yu., Gerasimchiuk R. P. Vitamin D receptor activators and vascular calcification. Nephrology and Dialysis. 2009; 11 (4): 276-291. In Russian. Земченков А. Ю., Герасимчук Р. П. Активаторы рецепторов витамина D и сосудистая кальцификация (обзор литературы). Нефрология и диализ. 2009; 11 (4): 276-291.

Dhingra R., Sullivan L. M., Fox C. S. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. ArchInternMed. 2007; 167:879-885.

Lavie C. J., Lee J. H., Milani R. V. Vitamin D and Cardiovascular Disease. Willitliveuptoitshype? JACC. 2011;58 (15): 1547-1556.

Kestenbaum B., Katz R., de Boer I., Hoofnagle A., Sarnak M. J., Shlipak M. G., Jenny N. S., Siscovick D. S. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. JACC. 2011; 58 (14): 1433-1441.

Schoen F. J., Levy R. J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79:1072-1080.

O'Brien K. D., Hippe D. S., Chen H., Neradilek M. B., Probstfield J. L., Peck S., Isquith D. A., Canton G., Yuan C., Polissar N. L., Zhao X.-Q., Kerwin W. S. Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging, Atherosclerosis. 2015, doi: 10.1016/j. atherosclerosis. 2015.11.032.

Lusher T. F. Ageing, inflammation, and oxidative stress: final common pathways of cardiovascular disease. European Heart Journal. 2015; 36: 3381- 3383 doi:10.1093/eurheartj/ehv679.

Isidori A. M., Giannetta E., Greco E. A., Gianfrilli D., Bonifacio V., Isidori A., Lenzi A., Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a metaanalysis. Clin Endocrinol (Oxf) 2005; 63: 280-293.

Ness J., Aronow W. S. Comparison of prevalence of atherosclerotic vascular disease in postmenopaual women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. AmJCardiol. 2006; 97: 1427-1428.

Kiel D. P., Kauppila L. I., Cupples L. A. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int. 2001; 68:271-276.

Parhami F., Morrow A. D., Balucan J. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation of the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 2007;17:680-687.

Parhami F., Basseri B., Hwang J., Tintut Y., Demer L. L. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002;91:570-576.

Corona G., Rastrelli G., Vignozzi L., Mannucci E., Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice & Research Clinical Endocrinology & Metabolism. 2011;25: 337-353.

Olson J. C., Edmundowicz D., Becker D. J. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes. 2000; 49:1571-1578.

The authors declare that there are no conflicts of interest present.